Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Dapagliflozin

Brand: Forxiga®
NICE TA: 418
Indication: Triple therapy for treating type 2 diabetes (NICE TA418)
Disease category: Endocrine system
Commissioning responsibility: CCG
PbR excluded: No

Background

Dapagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.
The LMMG recommends dapagliflozin as a 1st line ““gliflozin””.

Recommendation

LMMG recommendation: Green
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care

Supporting documents:

NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes

Algorithm For Antihyperglycaemic Therapy In Adults With Type II (Version 1.5) (454.0 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Green

Green

Green

Green

Green

Green